MENU
VRTX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Vertex Pharmaceuticals (VRTX) Earnings Date & Reports

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases... Show more

Industry: #Biotechnology
A.I. Advisor
published Earnings

VRTX is expected to report earnings to rise 12.59% to $4.74 per share on February 09

Vertex Pharmaceuticals VRTX Stock Earnings Reports
Q4'26
Est.
$4.74
Q3'26
Missed
by $0.15
Q2'26
Beat
by $0.01
Q1'26
Beat
by $0.14
Q4'25
Missed
by $0.05
The last earnings report on November 02 showed earnings per share of $4.21, missing the estimate of $4.36. With 654.50K shares outstanding, the current market capitalization sits at 138.67B.
A.I.Advisor
Nov 02, 2026

Vertex Pharmaceuticals (VRTX) Q3 2026 Earnings Recap: A New Growth Era Beyond Cystic Fibrosis

Key Takeaways

  • Vertex Pharmaceuticals reported third-quarter 2026 total revenue of $3.44 billion, up 12% year over year and modestly above consensus estimates.
  • Non-GAAP diluted earnings per share (EPS) came in at $4.76, roughly in line with the prior year's $4.80 and near analysts' expectations.
  • GAAP net income declined to $653.6 million, or $2.56 per share, reflecting acquisition-related costs from the Crinetics Pharmaceuticals deal.
  • The company raised full-year 2026 revenue guidance to a range of $13.15 billion to $13.25 billion.
  • Newer commercial franchises, including ALYFTREK, CASGEVY, JOURNAVX, and PALSONIFY, accelerated the company's diversification beyond cystic fibrosis.
  • A major near-term catalyst is the U.S. FDA's November 30, 2026 decision on povetacicept for IgA nephropathy.
  • For additional context on this ticker, explore Vertex's Major News, Today's Price Move, Price Targets, and Forecast pages.
  • Discover automated strategies across the market with Trending AI Robots.

Earnings Context and Why It Matters

Vertex Pharmaceuticals' third-quarter report matters because it captures a pivotal transition for one of biotech's most consistent large-cap performers. For years, the company's cystic fibrosis (CF) franchise anchored results, but the September 1 close of the roughly $9.0 billion (net of cash) Crinetics Pharmaceuticals acquisition added a fourth commercial pillar in rare endocrine disease. The quarter also tested whether newer launches such as ALYFTREK, CASGEVY, and JOURNAVX can offset maturing sales of TRIKAFTA/KAFTRIO. With a potential FDA approval for povetacicept in IgA nephropathy (IgAN, a kidney disease) due within weeks, investors are watching whether Vertex can convert pipeline momentum into a fifth commercial franchise.

Reported Results

Vertex reported total revenue of $3.44 billion for the third quarter of 2026, an increase of about 12% from $3.08 billion in the prior-year period. Non-GAAP (non-Generally Accepted Accounting Principles) diluted EPS was $4.76, compared with $4.80 a year earlier. GAAP net income fell to $653.6 million, or $2.56 per diluted share, versus $1.08 billion, or $4.20 per share, a decline the company attributed largely to expenses tied to the Crinetics acquisition.

By product, TRIKAFTA/KAFTRIO generated $2.44 billion, while the newer ALYFTREK contributed $705.8 million, up sharply from $247.0 million a year earlier. CASGEVY revenue reached $99.2 million (versus $16.9 million), JOURNAVX brought in $58.3 million (versus $19.6 million), and the newly added PALSONIFY recorded $10.1 million following the acquisition's September close. Management raised full-year 2026 revenue guidance to $13.15 billion to $13.25 billion, up from the prior $13.1 billion to $13.2 billion range.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable criteria such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and emerging market opportunities more efficiently than manual screening. For investors monitoring names like Vertex, it offers a structured way to compare opportunities and refine watchlists.

Market Reaction and Investor Sentiment

The stock's reaction was relatively muted. Shares closed down about 1% at $553.15 in the regular session before edging higher in after-hours trading, with various reports citing gains of roughly 1% to 5% following the print. The modest response reflected a quarter that landed largely in line with expectations: revenue slightly exceeded consensus, while adjusted EPS came in near or slightly below different analyst estimates depending on the source. Investors appeared to weigh the strong launch momentum across newer products and the raised guidance against acquisition-driven cost increases and the fact that the guidance midpoint remained slightly below some consensus figures.

Forward Outlook and Key Factors to Monitor

The most consequential near-term event is the FDA's decision on povetacicept for IgAN, expected on November 30, 2026. An approval would establish nephrology as Vertex's fifth commercial franchise and open a large, underserved patient population. Management has signaled it is fully prepared for launch, with a specialized field team already in place.

Beyond that, investors should monitor the continued ramp of ALYFTREK, CASGEVY, and JOURNAVX, which together have become an increasingly important growth engine. The company is also advancing multiple pipeline programs, including inaxaplin for APOL1-mediated kidney disease and suzetrigine in peripheral neuropathic pain, with data readouts expected in 2027.

Cost trends remain a key watch item, given the acquisition-related expenses and higher spending to fund pipeline and commercial initiatives. Margin trajectories and the pace of international reimbursement for newer products will also shape how efficiently the company converts its diversification strategy into durable earnings growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company that discovers and develops novel, small molecule pharmaceuticals

Industry Biotechnology

Industry
Biotechnology
Address
50 Northern Avenue
Phone
+1 617 341-6100
Employees
6400
Web
https://www.vrtx.com